Cargando…

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances

Oncolytic viruses are multifunctional anticancer agents with huge clinical potential, and have recently passed the randomized Phase III clinical trial hurdle. Both wild-type and engineered viruses have been selected for targeting of specific cancers, to elicit cytotoxicity, and also to generate anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simpson, Guy R, Relph, Kate, Harrington, Kevin, Melcher, Alan, Pandha, Hardev
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4996257/ https://www.ncbi.nlm.nih.gov/pubmed/27579292 http://dx.doi.org/10.2147/OV.S66083

Ejemplares similares

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
por: Heinemann, Lucy, et al.
Publicado: (2011)

The Hitchhiker's Guide to Virotherapy
por: Donnelly, Oliver, et al.
Publicado: (2012)

Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
por: Pandha, Hardev, et al.
Publicado: (2015)

Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors
por: Annels, Nicola E., et al.
Publicado: (2020)

Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
por: Kottke, Timothy, et al.
Publicado: (2021)

Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
por: Annels, Nicola E., et al.
Publicado: (2018)

Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21
por: Annels, Nicola E, et al.
Publicado: (2015)

Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy?
por: Prestwich, Robin J, et al.
Publicado: (2008)

Advances in oncolytic virotherapy
por: Russell, Stephen J., et al.
Publicado: (2022)

Oncolytic virotherapy for human malignant mesothelioma: recent advances
por: Boisgerault, Nicolas, et al.
Publicado: (2015)

Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?
por: Stepanenko, Aleksei A., et al.
Publicado: (2018)

Oncolytic Sendai virus-based virotherapy for cancer: recent advances
por: Saga, Kotaro, et al.
Publicado: (2015)

Targeting tumor vasculature through oncolytic virotherapy: recent advances
por: Toro Bejarano, Marcela, et al.
Publicado: (2015)

Oncolytic Virotherapy Treatment of Breast Cancer: Barriers and Recent Advances
por: Kwan, Amy, et al.
Publicado: (2021)

Oncolytic virotherapy: basic principles, recent advances and future directions
por: Lin, Danni, et al.
Publicado: (2023)

Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer
por: Nguyen, Andrew, et al.
Publicado: (2014)

ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012)

Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies
por: Roulstone, Victoria, et al.
Publicado: (2021)

Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy
por: Sampath, Padma, et al.
Publicado: (2015)

Oncolytic virotherapy for advanced liver tumours
por: Chang, Ju-Fang, et al.
Publicado: (2009)

Special Issue “Recent Advances in Morbillivirus Vaccine Development and Oncolytic Virotherapy”
por: Lin, Liang-Tzung
Publicado: (2020)

Combination strategies enhance oncolytic virotherapy
por: Friedman, Gregory K., et al.
Publicado: (2017)

Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
por: Wang, Xianwang, et al.
Publicado: (2023)

Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy
por: Zhang, Yalei, et al.
Publicado: (2021)

Editorial: Oncolytic virotherapy
por: Al-Shammari, Ahmed Majeed, et al.
Publicado: (2023)

Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy
por: Binz, Eike, et al.
Publicado: (2015)

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
por: Turnbull, Samantha, et al.
Publicado: (2015)

Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma
por: Morales-Molina, Alvaro, et al.
Publicado: (2021)

Combined oncolytic virotherapy gold nanoparticles as synergistic immunotherapy agent in breast cancer control
por: Jabir, Majid S., et al.
Publicado: (2023)

Prime-boost using Separate Oncolytic Viruses in Combination with Checkpoint Blockade Improves Anti-tumor Therapy
por: Ilett, Elizabeth, et al.
Publicado: (2016)

Oncolytic Virus Immunotherapy
por: Marchini, Antonio, et al.
Publicado: (2021)

Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy
por: Mamola, Joseph A., et al.
Publicado: (2023)

Oncolytic Virotherapy for Hematological Malignancies
por: Bais, Swarna, et al.
Publicado: (2012)

Oncolytic virotherapy – in vivo veritas
por: Kemler, Iris, et al.
Publicado: (2018)

Oncolytic Virotherapy in Glioma Tumors
por: Rius-Rocabert, Sergio, et al.
Publicado: (2020)

Delivery and Biosafety of Oncolytic Virotherapy
por: Li, Lizhi, et al.
Publicado: (2020)

Oncolytic Virotherapy with Myxoma Virus
por: Rahman, Masmudur M., et al.
Publicado: (2020)

Syncytia Formation in Oncolytic Virotherapy
por: Burton, Chase, et al.
Publicado: (2019)

Progress of oncolytic virotherapy for neuroblastoma
por: Chen, Xiao-Tong, et al.
Publicado: (2022)

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics
por: Harrington, K.J., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ve6h6sq4fgrp15vc77m93dh970